REDUCE LAP-HF II
Diseases of the Cardiovascular System
What is the purpose of this trial?
The primary objective of this randomized controlled clinical trial is to evaluate the clinical efficacy and safety of the IASD System II in symptomatic heart failure patients with an LV ejection fraction ≥40%, and elevated left sided filling pressures despite standard Guideline Directed Medical Therapy (GDMT).
- Ages40 years and older
- Trial withCorvia Medical, Inc.
- Start Date07/25/2017
- End Date12/30/2020
- Last Updated08/26/2020
- Study HIC#2000020740